File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: From molecular biology to targeted therapies for hepatocellular carcinoma: The future is now

TitleFrom molecular biology to targeted therapies for hepatocellular carcinoma: The future is now
Authors
KeywordsAngiogenesis
Epidermal growth factor
Hepatocellular carcinoma
Molecular-targeted therapy
Signaling pathways
Vascular endothelial growth factor
Issue Date2007
PublisherS Karger AG. The Journal's web site is located at http://www.karger.com/OCL
Citation
Oncology, 2007, v. 72 SUPPL. 1, p. 30-44 How to Cite?
AbstractHepatocellular carcinoma (HCC) is characterized as a highly chemoresistant cancer with no effective systemic therapy. Despite surgical or locoregional therapies, prognosis remains poor because of high tumor recurrence or tumor progression, and currently there are no well-established effective adjuvant therapies. The molecular biology of carcinogenesis and tumor progression of HCC has been increasingly understood with intense research in recent years. Several important intracellular signaling pathways such as the Ras/Raf/Mek/Erk pathway and PI3k/Akt/mTOR pathway have been recognized, and the role of several growth factors and angiogenic factors such as EGF and VEGF has been confirmed. Effective agents targeting these molecular abnormalities have been developed and widely tested in preclinical studies of HCC cell lines or xenograft models. Several agents have entered clinical trials in HCC patients, and recent data indicated that a multikinase inhibitor targeting Ras kinase and VEGFR-2, sorafenib, is effective in prolonging survival of patients with advanced HCC. The management of advanced HCC is entering the era of molecular targeting therapy, which is of particular significance for HCC in view of the lack of existing effective systemic therapy for this cancer. Copyright © 2007 S. Karger AG.
Persistent Identifierhttp://hdl.handle.net/10722/78269
ISSN
2015 Impact Factor: 2.152
2015 SCImago Journal Rankings: 0.920
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorPang, RWCen_HK
dc.contributor.authorPoon, RTPen_HK
dc.date.accessioned2010-09-06T07:41:01Z-
dc.date.available2010-09-06T07:41:01Z-
dc.date.issued2007en_HK
dc.identifier.citationOncology, 2007, v. 72 SUPPL. 1, p. 30-44en_HK
dc.identifier.issn0030-2414en_HK
dc.identifier.urihttp://hdl.handle.net/10722/78269-
dc.description.abstractHepatocellular carcinoma (HCC) is characterized as a highly chemoresistant cancer with no effective systemic therapy. Despite surgical or locoregional therapies, prognosis remains poor because of high tumor recurrence or tumor progression, and currently there are no well-established effective adjuvant therapies. The molecular biology of carcinogenesis and tumor progression of HCC has been increasingly understood with intense research in recent years. Several important intracellular signaling pathways such as the Ras/Raf/Mek/Erk pathway and PI3k/Akt/mTOR pathway have been recognized, and the role of several growth factors and angiogenic factors such as EGF and VEGF has been confirmed. Effective agents targeting these molecular abnormalities have been developed and widely tested in preclinical studies of HCC cell lines or xenograft models. Several agents have entered clinical trials in HCC patients, and recent data indicated that a multikinase inhibitor targeting Ras kinase and VEGFR-2, sorafenib, is effective in prolonging survival of patients with advanced HCC. The management of advanced HCC is entering the era of molecular targeting therapy, which is of particular significance for HCC in view of the lack of existing effective systemic therapy for this cancer. Copyright © 2007 S. Karger AG.en_HK
dc.languageengen_HK
dc.publisherS Karger AG. The Journal's web site is located at http://www.karger.com/OCLen_HK
dc.relation.ispartofOncologyen_HK
dc.rightsOncology. Copyright © S Karger AG.en_HK
dc.subjectAngiogenesisen_HK
dc.subjectEpidermal growth factoren_HK
dc.subjectHepatocellular carcinomaen_HK
dc.subjectMolecular-targeted therapyen_HK
dc.subjectSignaling pathwaysen_HK
dc.subjectVascular endothelial growth factoren_HK
dc.titleFrom molecular biology to targeted therapies for hepatocellular carcinoma: The future is nowen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0030-2414&volume=72 Suppl 1&spage=30&epage=44&date=2007&atitle=From+molecular+biology+to+targeted+therapies+for+hepatocellular+carcinoma:+the+future+is+nowen_HK
dc.identifier.emailPang, RWC: robertap@hkucc.hku.hken_HK
dc.identifier.emailPoon, RTP: poontp@hkucc.hku.hken_HK
dc.identifier.authorityPang, RWC=rp00274en_HK
dc.identifier.authorityPoon, RTP=rp00446en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1159/000111705en_HK
dc.identifier.pmid18087180-
dc.identifier.scopuseid_2-s2.0-37149004184en_HK
dc.identifier.hkuros150993en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-37149004184&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume72en_HK
dc.identifier.issueSUPPL. 1en_HK
dc.identifier.spage30en_HK
dc.identifier.epage44en_HK
dc.identifier.isiWOS:000251663400005-
dc.publisher.placeSwitzerlanden_HK
dc.identifier.scopusauthoridPang, RWC=7004376659en_HK
dc.identifier.scopusauthoridPoon, RTP=7103097223en_HK
dc.identifier.citeulike3343699-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats